Efficacy and safety of lenvatinib versus sorafenib in first-line treatment of advanced hepatocellular carcinoma: A meta-analysis

ObjectiveLenvatinib and sorafenib are first-line oral multikinase inhibitors approved for the treatment of advanced hepatocellular carcinoma (HCC). However, the choice of the primary therapeutic agent among these two remains controversial. This meta-analysis aimed to estimate the efficacy and safety...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Jia Luo, Benjian Gao, Zhiyu Lin, Hua Fan, Wen Ma, Danfei Yu, Qian Yang, Jing Tian, Xiaoli Yang, Bo Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-12-01
Subjects:	hepatocellular carcinoma lenvatinib sorafenib systemic therapy meta-analysis
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1010726/full